[Ad hoc-Mitteilung g
[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
24 avr. 2024 01h00 HE | F. Hoffmann-La Roche Ltd
Konzernverkäufe stiegen um 2%1 zu konstanten Wechselkursen (CER; -6% in CHF) dank starkem Wachstum der jüngeren Medikamente und Diagnostika; ohne COVID-19-Produkte nahmen die Konzernverkäufe um 7% zu;...
[Ad hoc announcement
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
24 avr. 2024 01h00 HE | F. Hoffmann-La Roche Ltd
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going...
roche-logo-blue.png
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
19 avr. 2024 01h00 HE | F. Hoffmann-La Roche Ltd
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung...
roche-logo-blue.png
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
17 avr. 2024 02h00 HE | F. Hoffmann-La Roche Ltd
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%)...
roche-logo-blue.png
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
15 avr. 2024 01h00 HE | F. Hoffmann-La Roche Ltd
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma Data from the...
roche-logo-blue.png
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
11 avr. 2024 01h00 HE | F. Hoffmann-La Roche Ltd
The Elecsys® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and CompanyOnce approved, the test will aid healthcare providers in...
roche-logo-blue.png
Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
26 mars 2024 12h45 HE | F. Hoffmann-La Roche Ltd
The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malariaMalaria is a serious and potentially fatal parasitic infection most commonly transmitted by...
roche-logo-blue.png
Roche Generalversammlung 2024
12 mars 2024 08h30 HE | F. Hoffmann-La Roche Ltd
Alle Anträge des Verwaltungsrates genehmigtSeverin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und Verwaltungsräte bestätigt 37....
roche-logo-blue.png
Assemblée générale 2024 de Roche
12 mars 2024 08h30 HE | F. Hoffmann-La Roche Ltd
Adoption de toutes les propositions du Conseil d’administrationRéélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil...
roche-logo-blue.png
Roche Annual General Meeting 2024
12 mars 2024 08h30 HE | F. Hoffmann-La Roche Ltd
All proposals of the Board of Directors approvedSeverin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election confirmed37th consecutive dividend...